The initiation of coverage by Cantor Fitzgerald with an Overweight rating and a price target of $25 indicates a positive outlook for Ambrx Biopharma. The analyst's belief that the peak sales potential of the company's ADCs pipeline is underappreciated suggests that the market may not be fully valuing the company's prospects. This could lead to a short-term increase in the stock price as investors reevaluate the company's potential.